Skip to main content

MEFISTO - Meniscal functionalised scaffold to prevent knee Osteoarthritis onset after meniscectomy

Objective

MEFISTO will develop two novel solutions to treat meniscus loss as a strategy for preventing the onset of an epidemic of post-meniscectomy knee osteoarthritis (OA) in Europe. Morphological profiling will identify the population of patients who, after meniscal resection, are at higher risk of early compartment degeneration, providing a personalized approach for the patient. The two different reconstructive strategies are: i) a controlled vascularized bioactive biodegradable meniscal scaffold, which will regenerate the native meniscus. This strategy will address younger patients with early osteoarthritic changes. ii) a bioactive non-biodegradable meniscal prosthesis, which will act as a mechanical unloading device and a drug delivery system, with the capacity to modulate the inflammatory environment. This strategy will address patients with advanced OA. A socio-economic analysis of the efficacy of existing meniscal substitutes will complete the project. This analysis is of vital importance for the European healthcare system, as it will provide a clear understanding of the costs and benefits of current clinical practice and predict the impact of the two new interventions. The technological innovation lies in the development of biologically active functionalized nanobiomaterials that can interact with the surrounding articular tissues. The biodegradable scaffold will promote revascularization in the peripheral zone, while leaving the inner zone avascular, reflecting the native meniscal tissue and functionalization with drug delivery micro/nanoparticles of the non-biodegradable device will provide modulation of inflammation. The impact is expected to be significant as so many patients have undergone or will undergo meniscectomy. The interventions developed in MEFISTO will prevent these patients from receiving joint-sacrificing procedures such as metal prosthesis whilst reducing the social burden, associated costs and high levels of morbidity resulting from OA.

Call for proposal

H2020-NMBP-TR-IND-2018
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

GEISTLICH BIOMATERIALS VERTRIEBSGESELLSCHAFT MBH
Address
Schneidweg 5
76534 Baden-baden
Germany
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 361 250

Participants (12)

HUMANITAS UNIVERSITY
Italy
EU contribution
€ 847 375
Address
Via Rita Levi Montalcini Snc
20090 Pieve Emanuele
Activity type
Higher or Secondary Education Establishments
KLINIKUM DER UNIVERSITAET REGENSBURG
Germany
EU contribution
€ 543 750
Address
Frans Josef Strauss Allee 11
93053 Regensburg
Activity type
Higher or Secondary Education Establishments
TISSUE CLICK LTD
United Kingdom
EU contribution
€ 381 250
Address
28 Sycamore Close
BN2 6SJ Brighton
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSIDAD DE SANTIAGO DE COMPOSTELA
Spain
EU contribution
€ 482 197,50
Address
Colexio De San Xerome Praza Do Obradoiro S/n
15782 Santiago De Compostela
Activity type
Higher or Secondary Education Establishments
UNIVERSITEIT ANTWERPEN
Belgium
EU contribution
€ 498 562,50
Address
Prinsstraat 13
2000 Antwerpen
Activity type
Higher or Secondary Education Establishments
CONSIGLIO NAZIONALE DELLE RICERCHE
Italy
EU contribution
€ 461 875
Address
Piazzale Aldo Moro 7
00185 Roma
Activity type
Research Organisations
ORTHOKEY ITALIA SRL
Italy
EU contribution
€ 253 125
Address
Piazza Nazioni Unite 15
54033 Carrara Ms
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ETABLISSEMENT FRANCAIS DU SANG
France
EU contribution
€ 216 875
Address
Avenue Du Stade De France 20
93210 La Plaine Saint Denis
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
ACTIVE IMPLANTS BV
Netherlands
EU contribution
€ 852 762,50
Address
Zijlweg 148B 0301, 3Hg
2015 BJ Haarlem
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
AIM GMBH - ASSESSMENT IN MEDICINE RESEARCH AND CONSULTING
Germany
EU contribution
€ 248 125
Address
Marie Curie Str. 8
79539 Lorrach
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Netherlands
EU contribution
€ 559 442,50
Address
Heidelberglaan 100
3584 CX Utrecht
Activity type
Higher or Secondary Education Establishments
SCIPROM SARL
Switzerland
EU contribution
€ 290 000
Address
Rue Du Centre 70
1025 Saint Sulpice
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)